The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease

Funding

No funding was sourced for this publication, which was undertaken as part of the KD research fellowship.

Conflict of interest

Ashish Srinivasan has served as a speaker for Sandoz and Terry White Chemart, and has received research support from Pfizer. Daniel Van Langenberg has received educational grants or research support from Pfizer, Takeda, Ferring and Shire, and has received consultancy and/or speaker’s fees from Pfizer, Janssen, AbbVie, Ferring, Vifor and Emerge Health. Krishneel Dutt has no conflicts of interest to declare.

Ethics

This study was approved by the Eastern Health Office for Research and Ethics (Reference LR54-2018).

Consent to participate

All individuals formally consented to participate in this study.

Consent for publication

All individuals included in this study formally consented for their de-identified data to be published.

Data availability statement

Eastern Health data were used in this study, which was previously collected for the study by Haifer et al. [1]. Patient questionnaires, pathology and clinician data are stored at the Monash Clinical School and Eastern Health databases.

Code availability

Not applicable.

Author contributions

KD: Literature review, manuscript planning, data analysis and preparation. AS: Data collection, manuscript planning and preparation. DvL: Manuscript planning, data analysis and preparation. All authors approved the submitted manuscript.

留言 (0)

沒有登入
gif